Aclaris Therapeutics Earnings Perspective: Return On Capital Employed
Portfolio Pulse from Benzinga Insights
Aclaris Therapeutics (NASDAQ:ACRS) reported Q1 sales of $2.53 million and a loss of $28.16 million, a 1.9% decrease from last quarter. The company posted a negative ROCE of -0.16%, suggesting inefficient capital allocation. Q1 earnings per share were $-0.42, beating analyst predictions of $-0.44.
May 22, 2023 | 2:57 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aclaris Therapeutics reported Q1 sales of $2.53 million and a loss of $28.16 million. The company's negative ROCE of -0.16% suggests inefficient capital allocation, which may impact stock price.
Aclaris Therapeutics reported a decrease in earnings and a negative ROCE, which indicates inefficient capital allocation. This could lead to concerns about the company's management and long-term success, potentially causing a negative impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100